{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Potential of Psilocybin Administration in Terminal Cancer Patients
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
To provide information on the use of psilocybin to treat depression and anxiety in terminal cancer patients.Learning Objectives
After completing this continuing education activity you will be able to:
- Analyze outcomes observed in various studies that used psilocybin for patients with terminal cancer.
- Outline the goals of future research that will treat terminal cancer patients with psilocybin.
Disclosures
The author, faculty, staff, and planners, including spouses/partners (if any), in any position to control the content of this CME/CNE activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity.
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- KY-BON 1.0 CH
- GA - BON 1.0 CH
Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0719
Published: Jul 2019
Expires: 12/31/2026
Sources:
Oncology Times
Required Passing Score: 7/10 (70%)
Specialties:
Oncology,
Psychiatric/Mental Health